Anastrozole
Arimidex
Anastrozole (Arimidex) is a potent oral non-steroidal (type II) aromatase inhibitor. It is FDA-approved for hormone-receptor-positive breast cancer in postmenopausal women; its use in men to raise testosterone or to control estradiol is off-label and studied only in small, short-term trials. It works by blocking the conversion of androgens to estrogens, which lowers estradiol and, in men, raises endogenous testosterone. The main dangers stem from driving estradiol too low: estrogen is essential for male bone health, so over-suppression can accelerate bone loss and fracture risk (clearly demonstrated in women in the ATAC trial), and can cause hot flashes/vasomotor symptoms, joint pain, adverse effects on mood and possibly lipids/cardiovascular risk, and impaired sexual function. Rare idiosyncratic liver injury has been reported. There is no adequate long-term human safety data for using anastrozole as an anabolic-steroid ancillary ("estrogen control"), and estradiol should never be crushed to near-zero. Anyone considering or using it needs baseline and follow-up bloodwork and an endocrinologist, not self-management.
Mechanism of action
Pharmacokinetics
Terminal elimination half-life approximately 40-50 hours in adults, supporting once-daily oral dosing and reaching steady state in about 7 days (class pharmacokinetic data for third-generation non-steroidal aromatase inhibitors).
Long-acting: near-maximal estradiol suppression is sustained across a 24-hour dosing interval; because of the ~2-day half-life and slow enzyme turnover, hormonal effects persist for several days after the last dose (relevant for washout, not for evading any test).
Oral; well absorbed. Absorption is not substantially affected by food.
Extensively hepatically metabolized (N-dealkylation, hydroxylation, glucuronidation) with the majority of a dose cleared by metabolism; metabolites and a small fraction of unchanged drug are excreted, predominantly via urine. Hepatic impairment can reduce clearance. Monitoring/washout implication only.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- In hypogonadal/older men, raises total and bioavailable testosterone into the normal range while modestly lowering estradiol (short-term RCTs).
- Increases the testosterone-to-estradiol ratio more than clomiphene, though clomiphene raised absolute testosterone more in a head-to-head trial.
- Lowers serum estradiol (the intended pharmacologic effect); degree of suppression is modest at 1 mg/day in men compared with the profound suppression seen in women.
- Testosterone increases may partially wane over 12 months of continued use even as estradiol stays suppressed.
- In short-term male trials, did not improve body composition, muscle strength, or hypogonadal symptom questionnaires despite normalizing testosterone.
- In pubertal boys with short stature, delays epiphyseal fusion and can increase predicted/near-final adult height (pediatric indication, not applicable to adult ancillary use).
Adverse effects by system
Short-term male RCTs (up to 12 months) showed no significant adverse change in fasting lipids, inflammatory markers (CRP, IL-6), adhesion molecules, or insulin resistance; however these were small and brief. Estradiol is cardioprotective in men, and lowering it correlated with rising triglycerides in some data, so long-term cardiovascular safety of estrogen suppression in men is unestablished.
Rare idiosyncratic drug-induced liver injury (cholestatic/hepatocellular, including jaundice and elevated transaminases) reported in isolated case reports; typically reversible on discontinuation. Not a predictable dose-related hepatotoxin.
Central pharmacologic action: lowers estradiol, which reduces estrogen negative feedback and raises LH/FSH and endogenous testosterone in men. Over-suppression of estradiol causes an estrogen-deficient state (bone, vasomotor, sexual, mood effects). Reduces estradiol-driven nocturnal growth hormone secretion.
Alters the sex-steroid milieu; low estradiol impairs libido and sexual function, and estradiol is needed for normal male sexual function and bone. In fertility/hypogonadism trials no significant change in semen parameters was seen over 12 weeks, but chronic estrogen suppression effects on spermatogenesis and sexual function are not well characterized long term.
Estrogen deficiency in men is associated with mood disturbance; low estradiol states and vasomotor symptoms can worsen wellbeing. Depression/low mood are plausible with excessive estradiol suppression, though male-specific controlled psychiatric data are limited (no adequate dedicated human data).
No characteristic direct nephrotoxicity identified in the reviewed human literature; no adequate data specific to renal harm. Dosing caution is driven by hepatic, not renal, clearance.
No clinically significant adverse hematologic effect (e.g., hematocrit) was observed in the 12-month male aromatase-inhibition RCT; raising testosterone can theoretically raise hematocrit but this was not demonstrated. No adequate long-term data.
Hot flashes/flushing (vasomotor) are the main estrogen-deficiency skin/thermoregulatory effect reported. Sweating reported. No consistent specific dermatologic toxicity beyond vasomotor symptoms in men.
HPTA suppression & recovery
Suppression: Anastrozole does not suppress the male HPTA; by reducing estrogen negative feedback it tends to raise LH, FSH, and endogenous testosterone. The risk is the opposite problem: over-suppression of estradiol producing an estrogen-deficient state.
Because it does not shut down the axis, its hormonal effects reverse over days-to-weeks after stopping as estradiol and gonadotropin feedback normalize; the testosterone-raising effect may also partially wane during continued use. Any use for hypogonadism or post-cycle hormonal recovery must be directed and monitored by an endocrinologist with serial bloodwork, individualized to the patient; self-directed titration risks driving estradiol too low. This monograph does not endorse combining agents.
Monitoring
Cadence: Baseline before any use, then re-check hormones and metabolic/liver panels at roughly 4-12 weeks after starting or dose change, and periodically (e.g., every few months) during continued use; DXA at baseline and repeated if use is prolonged. Cadence should be individualized by the prescribing clinician.
- Bone/joint pain, back pain, or a fragility fracture (possible bone loss)
- Persistent hot flashes, night sweats, low libido, erectile dysfunction, or low mood (signs of excessive estradiol suppression)
- Jaundice, dark urine, right-upper-quadrant pain, nausea, or unexplained fatigue (possible liver injury - stop and seek care)
- Symptoms suggesting estradiol driven too low - stop titrating and consult a clinician
Contraindications
- Premenopausal women / women who are or may become pregnant (Pregnancy Category X; fetal harm) and women who are breastfeeding.
- Known hypersensitivity to anastrozole.
- Men or contexts where estradiol is already low or bone density is compromised (osteoporosis/osteopenia, prior fragility fracture) - aromatase inhibition can worsen bone loss.
- Relative caution in significant hepatic impairment (extensive hepatic clearance) and in anyone with a history of anastrozole-associated liver injury.
- No established, safety-validated indication for use as an anabolic-steroid ancillary; use in that context is unproven and unsupervised use is strongly discouraged.
Interaction profile
- ModerateWith another aromatase inhibitor: Hormonal
- ModerateWith a SERM: Hormonal
- ModerateWith an anabolic steroid: Hormonal
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- Do not crush estradiol to near-zero: estrogen is essential for male bone, cardiovascular, sexual, and cognitive health; over-suppression is a real harm, not a goal. Male trial data suggest keeping estradiol at a clinically adequate level (roughly >=10-20 pg/mL) to protect bone.
- Use is off-label in men and unproven as an anabolic-steroid ancillary - there is no adequate long-term human safety data for that context. Involve a physician/endocrinologist rather than self-managing.
- Get baseline bloodwork (sensitive estradiol, total/free testosterone, LH/FSH, lipids, LFTs, CBC) and a DXA scan before prolonged use, and recheck periodically.
- Stop and seek medical care for signs of liver injury (jaundice, dark urine, right-upper-quadrant pain, unexplained nausea/fatigue).
- Stop titrating and consult a clinician if you develop bone/joint pain, a fracture, persistent hot flashes, low libido, erectile dysfunction, or low mood - these can signal excessive estradiol suppression.
- This is a single-agent monograph; it does not endorse or describe combining anastrozole with other hormone-modulating drugs. Any recovery/HPTA management should be individualized by an endocrinologist.
- Women who are or could become pregnant must not use anastrozole (fetal harm).
Citations (15)
Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.
- 01
Anastrozole is a third-generation non-steroidal aromatase inhibitor; pharmacokinetics (half-life, oral route, hepatic metabolism/clearance) support once-daily dosing.
ReviewPharmacokinetics of third-generation aromatase inhibitors.PMID 14513434 ↗
- 02
Anastrozole inhibits aromatase, lowering estradiol and raising testosterone in men; in elderly mildly hypogonadal men 1 mg/day raised bioavailable testosterone and modestly lowered estradiol over 12 weeks without adverse effect on bone turnover markers or BMD short-term.
- 03
Over 12 months in older hypogonadal men, anastrozole normalized testosterone and modestly lowered estradiol, but testosterone peaked at 3 months then declined, and there was no improvement in body composition, strength, PSA, hematocrit, or lipids.
- 04
In a randomized double-blind trial in hypogonadal infertile men, anastrozole raised testosterone and increased the testosterone-to-estradiol ratio (lowering estradiol), while clomiphene produced a higher absolute testosterone; no significant change in semen parameters over 12 weeks.
- 05
Estrogen (estradiol) is the primary regulator of bone homeostasis in adult men; suppressing aromatization of testosterone increased bone resorption and reduced BMD, with estradiol above ~10 pg/mL and testosterone above ~200 ng/dL generally needed to prevent bone loss.
- 06
In postmenopausal breast cancer, anastrozole increased arthralgia and fractures compared with tamoxifen (ATAC trial), demonstrating the bone-loss/fracture risk of aromatase inhibition.
- 07
During adjuvant anastrozole therapy in postmenopausal women, joint pain and reduced bone mineral density with bone fractures were observed; bisphosphonate co-treatment mitigated BMD loss.
CohortPMID 19526308 ↗
- 08
Short-term anastrozole in elderly hypogonadal men did not significantly worsen fasting lipids, inflammatory markers (CRP, IL-6), adhesion molecules, or insulin resistance, though falling estradiol correlated with rising triglycerides.
- 09
Estradiol deficiency is the key mediator of vasomotor symptoms (hot flashes) in men, shown when aromatization was blocked with anastrozole.
- 10
Estradiol amplifies nocturnal growth hormone secretion in men; aromatase inhibition with anastrozole reduces this estrogen-driven GH secretion.
- 11
Anastrozole added to testosterone in hypogonadal men with epilepsy lowered estradiol and triglycerides; sexual-function benefit over placebo was not statistically significant.
- 12
Selectively reducing estradiol with anastrozole (while maintaining testosterone) did not impair insulin sensitivity in men, whereas testosterone withdrawal did.
- 13
Anastrozole can cause rare idiosyncratic drug-induced liver injury (cholestatic/hepatocellular, with jaundice and elevated liver enzymes), reversible on discontinuation.
Case reportPMID 33240477 ↗
- 14
First reported case of anastrozole-induced hepatotoxicity, supporting hepatotoxicity as a rare idiosyncratic event.
Case reportPMID 17033446 ↗
- 15
In pubertal boys with idiopathic short stature, aromatase inhibitors (anastrozole/letrozole) delayed bone maturation and increased height potential with a short-term safety profile similar to comparators (pediatric context).
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice